QUANTA-SYSTEM
Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of precision and versatility in a device that allows you to select the picosecond pulse-duration to personalize the treatments to meet the unique needs of each person.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130556983/en/
Pico Filling Treatment - skin rejuvenation (Photo: Business Wire)
Quanta System has always been committed to follow the evolving needs of the market and to listen and understand the needs of its customers. Discovery PICO VarioPulse Technology® represents a significant leap forward in the world of aesthetic medicine.
Featuring Pico Boost technology that can deliver up to 1.8GW of laser power perfectly controlled by the VarioPulse Technology®, this next-generation device welcomes you to 3 cutting-edge customized treatments that are precisely designed to perform tattoo removal and skin revitalization at their best.
Pico Tune-Ink, the adaptable treatment that removes tattoo ink of a wide variety of colour and complexity;
Pico Filling, the no down-time treatment that revitalizes the skin from within and improve its appearance;
Pico Plasma, the all round skin remodeling treatment that targets scars and acne scars.
Commenting on this major launch, Girolamo Lionetti, CEO of Quanta System, expresses his excitement, "We are thrilled to bring this new technology to the aesthetic world. Our primary goal of improving people's quality of life is greatly enhanced by continuing to work alongside our valued partners, the physicians, and providing patients with more and more customized treatments.”
This is just the first step of a new era laser roadmap focused on delivering the superior user experience and patient satisfaction that the market has been waiting for.
For more information about Discovery PICO VarioPulse Technology®, visit our website www.quantasystem.com or come to discover it in person at IMCAS Booth U322 Level 3 - February 1st -3rd 2024.
About Quanta System
For almost forty years Quanta System, a 100% Italian company distributed worldwide, is the reference point for the research, designing and manufacture of state-of-the-art laser systems for surgery, dermatology and aesthetic medicine and the conservation of art works.
In 2004 the company joins El.En. SpA, leader on the laser market listed on the Euronext STAR Milan ("STAR") of the Italian Stock Exchange and a partner of reference for health facilities, Institutions and Entities engaged in scientific and research projects at a global level.
Designed to be used by doctors, specialised operators and restorers, today the Quanta System lasers represent the "Gold Standard" thanks to a wide range of applications.
The laser systems are entirely manufactured in Italy: from Research & Development to production, the entire process takes place in the company's headquarters in Samarate (in the province of Varese).
Quanta System is a trusted partner, day in day out, of all doctors in every part of the world thanks to its ability to listen, its straightforward debates and the creation of new systems that increasingly meet the real needs of professionals so they can provide better care for their patients.
A constantly evolving company that has managed to update its production so that it has always managed to satisfy the developing needs of its time, without losing sight of its primary objective: contributing to the improvement of people's quality of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130556983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium4.11.2025 16:04:00 CET | Press release
Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRIFirst-of-its-kind single intratumoral injection for MBC to the spineTreated lesions showed full bone regeneration with reconstitution of trabecular bone, and no skeletal related events; mean lesion defect volume decreased by 87.9% at day 180.Therapeutic spread extended to nearby non-treated lesions, also achieving complete response within the same vertebral body Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 10, 2025. The abstract
ID5 Acquires TrueData, Combining Strengths to Create the Most Comprehensive Identity Solution for Digital Advertising4.11.2025 16:00:00 CET | Press release
Acquisition creates a global privacy-focused identity powerhouse and enhances value for partners through expanded capabilities ID5, the market-leading ID provider for digital advertising, has today announced the acquisition of TrueData, a top-tier US-based identity graph company. The deal represents a major step forward in ID5’s growth strategy, significantly strengthening its presence in the US and broadening the value it can deliver to partners worldwide. ID5, recognized as a global leader in the alternative ID space, has built a strong foothold in the US, where the majority of its clients and revenue originate. By bringing in TrueData’s graph, the company is expanding its operations in the US and strengthening its Adaptive Identity technology with new datasets and expertise. The combination of TrueData’s graph and expertise with the GDPR compliant ID5 Graph, and its scaled alternative ID creates a unique proposition in the market, connecting offline data with the largest online reac
Westlake Announces Proposed Offering of Senior Notes4.11.2025 15:15:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of an underwritten public offering, subject to market and other conditions, of senior unsecured notes (the “Notes”) under its existing shelf registration statement. The timing of pricing and terms of the Notes are subject to market conditions and other factors. Westlake intends to use the net proceeds from the proposed public offering of the Notes to fund the repurchase of its outstanding 3.600% Senior Notes due 2026 (the “2026 Senior Notes”) pursuant to a concurrent cash tender offer (the “Tender Offer”) for any and all of the 2026 Senior Notes. Westlake anticipates using any remaining net proceeds to fund the purchase price of its pending acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (the “ACI Acquisition”) and for general corporate purposes, including working capital management. The offering of the Notes is not contingent upon the successful completion of the Tende
Westlake Announces Cash Tender Offer4.11.2025 15:13:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of a cash tender offer to purchase (the “Offer”) any and all of the outstanding 3.600% Senior Notes due 2026 (the “Notes”) as set forth in the table below. The tender offer is being made solely pursuant to the terms and conditions set forth in an Offer to Purchase, dated November 4, 2025 (the “Offer to Purchase”). Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the tender offer. The tender offer is not conditioned on any minimum amount of the Notes being tendered. Subject to applicable law, Westlake may amend, extend or terminate the tender offer in its sole discretion. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Series of Notes CUSIP Numbers(1) Aggregate Principal Amount Outstanding U.S. Treasury Reference Security(2) Bloomberg Reference Page(2) Fixed Spread(3) 3.600% S
In-House Counsel Warn of Mounting Risks as Service of Process Volume Surges4.11.2025 15:00:00 CET | Press release
93% of in-house counsel say mass arbitration is increasing SOP risk and complexity59% report varying state requirements are driving compliance errors97% use AI for managing or analyzing SOP, yet 96% remain concerned about accuracy and speed The volume of service of process (SOP)—the legal procedure by which one party formally notifies another of a legal action—is surging across the U.S., amplifying operational pressure and compliance risk for in-house legal teams. This is according to a new nationwide study commissioned by CSC, industry-leading registered agent and compliance service provider. CSC surveyed 250 senior in-house counsel across the U.S. and found that rising SOP volume and growing concerns around data accuracy are intensifying both risk and workload pressure.1 Respondents cited data accuracy as a significant challenge to SOP management (61%), followed by rising SOP volume (56%). More than three-quarters (76%) said their departments are spending “too much” or “excessive” ti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom